{'fraction_non_alphanumeric': 0.024965325936199722, 'fraction_numerical': 0.011095700416088766, 'mean_word_length': 5.446428571428571, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Use of Tofacitinib Has a Potential Effect on Improving the Outcomes of Melanoma Differentiation-Associated Gene 5-Related Interstitial Lung Disease.

We read with great interest the recent retrospective analysis by Fan and colleagues on the outcomes of tofacitinib (TOF) or tacrolimus (TAC) in combination with glucocorticoids for melanoma differentiation-associated gene 5 (MDA5)-related interstitial lung disease (MDA5-ILD), published in The Journal of Rheumatology 1 The authors mainly investigated whether TOF exposure was associated with reduced mortality at 6 months and 1 year, and also compared the incidence of adverse events and discontinuation rates in the TOF and TAC groups for the treatment of MDA5-ILD.